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PREVIEW AND META-ANALYSIS
Metabolic Syndrome and Risk of
Incident Cardiovascular Events and Death
A Systematic Review and Meta-Analysis of Longitudinal Studies
Apoor S. Gami, MD,*† Brandi J. Witt, MD,*† Daniel E. Howard, MD,† Patricia J. Erwin, MLS,‡
Lisa A. Gami, RN,*† Virend K. Somers, MD, PHD, FACC,*†§ Victor M. Montori, MD, MSC†¶
Rochester, Minnesota
Objectives The purpose of this research was to assess the association between the metabolic syndrome (MetSyn) and car-
diovascular events and mortality by meta-analyses of longitudinal studies.
Background Controversy exists regarding the cardiovascular risk associated with MetSyn.
Methods We searched electronic reference databases through March 2005, studies that referenced Reaven’s seminal
article, abstracts presented at meetings in 2003 to 2004, and queried experts. Two reviewers independently
assessed eligibility. Longitudinal studies reporting associations between MetSyn and cardiovascular events or
mortality were eligible. Two reviewers independently used a standardized form to collect data from published
reports. Authors were contacted. Study quality was assessed by the control of selection, detection, and attrition
biases.
Results We found 37 eligible studies that included 43 cohorts (inception 1971 to 1997) and 172,573 individuals. Ran-
dom effects meta-analyses showed MetSyn had a relative risk (RR) of cardiovascular events and death of 1.78
(95% confidence interval [CI] 1.58 to 2.00). The association was stronger in women (RR 2.63 vs. 1.98, p 
0.09), in studies enrolling lower risk (10%) individuals (RR 1.96 vs. 1.43, p  0.04), and in studies using factor
analysis or the World Health Organization definition (RR 2.68 and 2.06 vs. 1.67 for National Cholesterol Educa-
tion Program definition and 1.35 for other definitions; p  0.005). The association remained after adjusting for
traditional cardiovascular risk factors (RR 1.54, 95% CI 1.32 to 1.79).
Conclusions The best available evidence suggests that people with MetSyn are at increased risk of cardiovascular
events. These results can help clinicians counsel patients to consider lifestyle interventions, and should fuel
research of other preventive interventions. (J Am Coll Cardiol 2007;49:403–14) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.032r
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she metabolic syndrome (MetSyn), also termed the insulin
esistance syndrome, is the concurrence in an individual of
ultiple metabolic abnormalities associated with cardiovas-
ular disease. Cross-sectional surveys indicate that, in the
.S., one-third of adults (1) and an alarming proportion of
hildren (2) have the MetSyn. It represents a global public
ealth problem (3,4). Since 1988, when Reaven (5) first
ystematically described it, an abundance of research has
dvanced an understanding of the pathophysiology, epide-
iology, prognostic implications, and therapeutic strategies
rom the *Division of Cardiovascular Diseases, †Department of Internal Medicine,
Mayo Medical Libraries, §Division of Hypertension, Division of Endocrinology,
utrition, and Metabolism, and ¶Knowledge and Encounter Research Unit, Mayo
linic College of Medicine, Rochester, Minnesota. Dr. Gami had full access to all of
he data in this study and takes responsibility for the integrity of the data and the
ccuracy of the data analysis.a
Manuscript received June 26, 2006; revised manuscript received September 1, 2006,
ccepted September 27, 2006.elated to the MetSyn. Despite this progress, fundamental
ncertainties persist regarding the MetSyn, as highlighted
y recent national and international diabetes organizations’
oubt regarding even its existence (6).
Reaven’s (5) first definition of the MetSyn included these
omponents: hyperglycemia, abdominal obesity, hypertri-
lyceridemia, low high-density lipoprotein cholesterol con-
entration, and hypertension. Its pathogenesis, unified by
he putative mechanism of insulin resistance, was thought to
e related to interactions between sedentary lifestyle, diet,
nd genetic factors. In 1998, the American Diabetes Asso-
iation proposed that MetSyn is comprised of glucose
ntolerance, central obesity, dyslipidemia (including in-
reased triglycerides, decreased high-density lipoprotein
holesterol concentration, and increased small dense low-
ensity lipoprotein cholesterol concentration), hyperten-
ion, increased prothrombotic and antifibrinolytic factors,
nd risk for atherosclerotic disease; but, it did not propose
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for these processes (7). In 1999,
the World Health Organization
(WHO) codified specific compo-
nents and thresholds for the
MetSyn (8), and in 2003 the
U.S. National Cholesterol Edu-
cation Program (NCEP) re-
defined the MetSyn in an at-
tempt to simplify the clinical
application of its criteria and im-
prove its recognition (9). Despite
these efforts, there exists no gen-
ine consensus of the unique components that comprise the
etSyn (4,10). Burgeoning information regarding its
athophysiology adds to the uncertainty (11).
Only recently have there been studies assessing the risk of
ncident cardiovascular disease events attributable to the
etSyn. These studies had different populations, defini-
ions of MetSyn, methods, and results. Because of this
ariability and the current controversy regarding its impli-
ations (6), we propose that a systematic review and meta-
nalysis of the existing data will provide the current best
vidence. In addition to providing an overall estimate of
isk, the tools of meta-analysis allow an evaluation of
ifferences between studies that could clarify the prognostic
mplications of how MetSyn is defined, in which settings it
ay be informative, and other issues related to its clinical
se (12,13).
We performed a meta-analysis of longitudinal studies
hat assessed any cardiovascular event outcomes or mortality
n people with clustering of 3 or more coronary risk factors
regardless of whether this was termed the MetSyn) com-
ared with people without that phenotype. We expected to
apitalize on the high heterogeneity between studies to
dentify likely explanations for it in factors related to
opulation characteristics, outcome and exposure ascertain-
ent, and study quality. The reporting of this systematic
eview follows current standards (14).
ethods
tudy eligibility. Eligible studies: 1) were randomized
rials or cohort studies; 2) reported a risk estimate (or
requency data from which one could be calculated) for
etSyn, its synonyms, or clustering of 3 or more coronary
isk factors; and 3) reported a single or combined cardio-
ascular event outcome or mortality. There were no exclu-
ion criteria or language restrictions.
earch strategy. A content expert and a master’s level
edical librarian with extensive meta-analytical experience
ollaborated to design the search strategies. We searched
he following electronic databases on March 1, 2005: Ovid
EDLINE (from 1966), Ovid EMBASE (from 1988),
eb of Science (from 1993), and Cochrane Library (from
Abbreviations
and Acronyms
CI  confidence interval
MetSyn  metabolic
syndrome
NCEP  National
Cholesterol Education
Program
RR  relative risk
WHO  World Health
Organizationnception). Our search of Web of Science included a match aetween terms for cardiovascular outcomes and publications
hat cited Reaven’s article (5). Figure 1 shows the strategy
or MEDLINE (the other strategies are available from the
uthors).
We hand-searched conference proceedings from the 2003
nd 2004 annual scientific sessions of the European Society
f Cardiology, American Heart Association, American
ollege of Cardiology, and American Diabetes Association
or relevant abstracts to identify full peer-reviewed publica-
ions not yet indexed. We queried experts of endocrinology
nd cardiology, and we reviewed bibliographies of retrieved
ublications to further increase our yield of potentially
elevant articles.
tudy selection. Using a high threshold for exclusion, one
nvestigator examined all abstracts and selected articles for
ull text examination. Two investigators independently used
iloted, standardized forms to assess the eligibility of all full
ext articles. We collaborated with translation services to
xamine articles in languages other than English. We
ssessed interobserver agreement by the phi and kappa
tatistics (15,16), and we resolved differences by consensus.
ata collection. Two investigators independently used
iloted, standardized forms to abstract data from included
tudies and other publications reporting their methods. We
ontacted original study authors in order to obtain missing
ata.
For each study, we recorded the year of cohort inception,
he setting (community subjects vs. medical patients), par-
icipant characteristics related to the MetSyn, and the
umber of participants with prevalent coronary heart disease
nd diabetes mellitus. Exposure data collected included the
efinitions and criteria for MetSyn and its components, the
umber of participants with and without MetSyn for each
efinition, and the duration of follow-up. Outcome data
ollected included the definitions of cardiovascular out-
omes, the numbers of participants with and without
etSyn who did and did not have the outcome(s), the
ultivariable adjusted risk estimate (relative risk [RR],
azard ratio, or odds ratio) for MetSyn and for different
umbers of its components for each outcome, and the
ariables incorporated into the multivariable analyses. When
study reported only risk estimates for different numbers of
etSyn components, rather than a risk estimate for MetSyn
r 3 or more components, we used the risk estimate for 3
omponents to reflect that of the MetSyn (an approach that
ould underestimate the risk).
uality assessment. We measured the quality, or internal
alidity, of studies by assessing their control of selection
ias, detection bias, and attrition bias (17). For control of
election bias, we assessed if multivariable risk estimates
ncorporated age, gender, smoking, and coronary heart
isease history, when applicable. For control of detection
ias, we assessed if the outcome assessors were unaware
either explicitly or de facto due to temporal relationships)
f subjects’ MetSyn status. For control of attrition bias, we
ssessed the extent of loss to follow-up.
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January 30, 2007:403–14 Meta-Analysis of Metabolic SyndromeLoss to follow-up is traditionally represented as a pro-
ortion of the total initial study population, but this
pproach does not provide sufficient information about how
oss to follow-up in a study affects the reliability of its risk
stimate. In this study, we describe attrition bias by the ratio
f the number of subjects lost to follow-up to the number of
utcome events in the study (loss-events ratio). This is a
irect measure of how influential loss to follow-up could be
or a risk estimate in a given study, and we arbitrarily
onsidered a loss-events ratio 10% as satisfactory control
f attrition bias.
tatistical analysis. The results of each cohort study were
eported as an RR, hazard ratio, odds ratio, or dichoto-
ous frequency data. We treated hazard ratios as RRs.
ecause event rates were not sufficiently low in some
igh-risk study populations, we did not assume that odds
atios were comparable to RRs. We algebraically con-
erted odds ratios and frequency data into RRs. When
vailable, we used the adjusted risk estimates from
ultivariate models.
We performed separate meta-analyses with the DerSi-
onian and Laird (18) random effects model to obtain the
ooled RR for each outcome and the pooled RR for the
Figure 1 Literature Search Strategy Used for the MEDLINE Datrimary end point of incident cardiovascular events and death. aor the latter, when studies reported multiple outcomes, we
ncorporated them into subsequent analyses based on the
ollowing hierarchical list of outcomes (from broader to
ore specific cardiovascular outcomes, followed by all-cause
ortality): cardiovascular events, coronary heart disease
vents, cardiovascular death, coronary heart disease death,
nd all-cause death. Similarly, when studies reported results
ased on multiple MetSyn criteria, we incorporated them
ased on the following hierarchical list of criteria: NCEP,
odified NCEP, WHO, modified WHO, and other crite-
ia. We used the Cochran’s Q test to assess between-study
ifferences and the I2 statistic to quantify the proportion of
bserved inconsistency across study results not explained by
hance (19). We proposed pre-defined subgroup analyses to
est the effect of methodology and participant characteristics
n the strength of association. Heterogeneity between
ubgroups was calculated with Cochran’s Q test (20), and
omparisons of risk estimates between subgroups were made
ith a test of interaction (21).
Using the same methods, we performed an additional
eta-analysis of studies that reported a risk estimate for
etSyn that was adjusted in multivariable models for any or
ll of the components that make up the syndrome. This
enalysis aimed to quantify the additive cardiovascular risk
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Meta-Analysis of Metabolic Syndrome January 30, 2007:403–14ttributable to the MetSyn above that which is conferred by
ts component risk factors.
The presence of publication bias was investigated graph-
cally by the method of Sterne and Egger (22), and its
mplications for our results were assessed by the fail-safe n
23) and the trim-and-fill method (24).
All analyses were performed with Comprehensive Meta
nalysis Version 2 (Biostat, Englewood, New Jersey) (25).
ata Synthesis
earch results and study inclusion. Our initial search
dentified 4,198 unique publications, which were narrowed
y preliminary review to 104 potentially relevant original
rticles. The search of conference proceedings and query of
xperts did not identify additional articles. Sixty-seven
rticles were excluded (some for multiple reasons) because of
ross-sectional study design (n  10), lack of measurement
r report of outcome data for MetSyn, its synonyms, or
lustering of 3 or more coronary risk factors (n  61), or
ack of measurement of cardiovascular events or death (n 
). There were 37 eligible reports (interobserver raw agree-
ent 96%,  0.93,  0.91). One article that studied the
ame cohort as another included article was excluded (26),
nd 1 article presented results for 2 independent studies
27). In another study, the investigators performed 11
ohort studies (by applying modified MetSyn criteria to
xisting baseline subject data from 11 prior epidemiologic
tudies that assessed mortality during long-term follow-up)
nd reported a pooled result for 7 of those cohorts (28).
ltimately, our meta-analysis included 36 reports that
escribed 37 studies including 43 unique cohorts (Fig. 2)
27–62).
Figure 2 Flowchart of Article Inclusion
*The 36 included articles described 37 studies that included 43 unique cohorts.ualitative summary. Table 1 summarizes the character-
stics of the included studies. They were all published since
998, included cohorts with inception between 1971 and
997, and had follow-up from 2.2 to 18.8 years. Sample
izes ranged from 133 to 41,056 participants (total
72,537), and there was a wide range of prevalence of
ardiovascular disease and diabetes mellitus at inception.
The MetSyn was defined by WHO criteria in 6 studies
36,41,47,48,51,61), NCEP criteria in 12 studies
39,40,42,43,47,53–55,57,59,61,62), modified WHO criteria
n 4 studies (28,39,54,58), and modified NCEP criteria in 10
tudies (27,39,44–46,49,50,56,60). Most modifications substi-
uted body mass index for waist circumference or waist-to-hip
atio, or omitted the proteinuria component of the WHO
riteria. A few studies added additional components, such as
-reactive protein (45) and uric acid (38,52). Factor analysis
as used in 5 studies (31,33,34,39,52) to create a novel
ariable, or factor, comprised of statistical loadings of highly
nter-correlated participant characteristics (analogous to clus-
ered risk factors in the MetSyn), which was then used as a
arameter in regression models for incident cardiovascu-
ar disease. The factors in these studies were nearly
dentical to the components in WHO and NCEP defi-
itions of MetSyn. Some studies developed MetSyn
riteria using threshold values for its components based
n the extreme tertiles to quintiles of their distribution
30,32,35,37). One study that presumably had a predom-
nantly Japanese population used a lower threshold for
ystemic obesity (a body mass index 25 kg/m2) in its
odified WHO criteria (58), but no other studies mod-
fied their criteria to account for ethnic differences.
Eleven studies assessed cardiovascular events (which in
ome studies included cardiovascular death), 18 studies
Characteristics of Cohort Studies of Metabolic Syndrome and Incident Cardiovascular Disease and Death
Table 1 Characteristics of Cohort Studies of Metabolic Syndrome and Incident Cardiovascular Disease and Death
Study Author, Year
Cohort
Inception Year
Follow-Up,
yrs Setting
Sample
Size, n
Mean
Age, yrs
Men,
%
CVD,
%
DM,
% MS Criteria
MS,
% Outcomes
Controlled
Selection Bias
Controlled
Attrition Bias
Anderson et al., 2004 (46) 1994 2.8 M 2,035 65 76 100 30 Modified NCEP 66 CHD events ✓ ✓
Bonora et al., 2003 (a) (41) 1990 5.0 C 888 59 51 10 23 WHO
NCEP
34
18
CHD events ✓
Bonora et al., 2004 (b) (47) 1988 4.3 M 559 63 45 0 100 WHO 91 CV events ✓
Bruno et al., 2004 (48) 1991 8.2 M 1,565 69 43 24 100 WHO 76 Death
CV death
✓ ✓
Corsetti et al., 2004 (49) 1994 2.2 M 766 58 77 100 0 Modified NCEP 36 CHD events ✓
Ford, 2004 (50) 1976 13.5 C 2,431 50 46 18 3 Modified NCEP 26 Death
CV death
CHD death
✓ X
Gimeno Orna et al., 2004 (51) 1994 4.6 M 318 65 41 21 100 WHO 77 CV events
CHD events
✓
Girman et al., 2004 (a) (27) 1988 5.4 M 1,991 59 81 100 0 Modified NCEP 21 CHD events ✓
Girman et al., 2004 (b) (27) 1986 5.0 C 3,188 58 85 0 0 Modified NCEP 46 CHD events ✓
Godsland et al., 2004 (52) 1971 10.6 C 649 47 100 0 0 Factor analysis NA CHD events
Holvöet et al., 2004 (53) 1997 5.0 C 3,033 74 48 13 19 NCEP 38 CHD events ✓ ✓
Hsia et al., 2003 (42) 1997 2.8 M 294 65 0 100 37 NCEP 60 CHD death
CV events
CHD events
Hu et al., 2004 (28) NA 8.5 C 9,522 56 46 X 0 Modified WHO 15 Death
CV death
✓
Hunt et al., 2004 (54) 1984 12.7 C 2,815 43 43 7 11 NCEP
Modified WHO
25
25
Death
CV death
Isomaa et al., 2001 (36) 1990 6.9 M 4,483 54 48 6 38 WHO 46 Death
CV death
✓
Katzmarzyk et al., 2004 (55) 1979 10.2 M 19,223 43 100 0 1 NCEP 20 Death
CV death
✓ ✓
Kaukua et al., 2001 (37) 1979 10.0 M 133 56 53 32 100 Other 54 Death
CV death
✓
Klein et al., 2002 (38) 1988 4.8 C 2,957 62 43 0 0 Other 19 CV events
Lakka et al., 2002 (39) 1984 11.6 C 1,209 52 100 0 0 NCEP
Modified NCEP
Modified WHO-1
Modified WHO-2
Factor analysis
9
14
14
13
NA
Death
CV death
CHD death
✓ ✓
Lehto et al., 2000 (33) 1982 7.2 M 902 58 55 15 100 Factor analysis NA CHD death ✓
Lempianin et al., 1999 (31) 1986 7.0 C 1,069 69 37 20 0 Factor analysis NA CHD events X ✓
Malik et al., 2004 (56) 1976 13.0 C 6,255 50 46 27 13 Modified NCEP 27 Death
CV death
CHD death
✓ ✓
Marroquin et al., 2004 (57) 1996 3.5 M 755 58 0 38 32 NCEP 57 Death
CV events
✓
McNeill et al., 2005 (62) 1987 11.0 C 12,089 54 43 0 0 NCEP 23 CHD events ✓ ✓
Continued on next page
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Table 1 Continued
Study Author, Year
Cohort
Inception Year
Follow-Up,
yrs Setting
Sample
Size, n
Mean
Age, yrs
Men,
%
CVD,
%
DM,
% MS Criteria
MS,
% Outcomes
Controlled
Selection Bias
Controlled
Attrition Bias
Nakanishi et al., 2004 (58) 1994 7.0 C 6,182 48 100 0 7 Modified WHO 7 CV events ✓
Onat et al., 2002 (40) 1997 3.0 C 2,398 49 50 8 6 NCEP 33 CHD events ✓
Pyörälä et al., 2000 (34) 1971 18.8 C 970 48 100 0 0 Factor analysis NA CV events
CHD events
✓ ✓
✓
Resnick et al., 2003 (43) 1989 7.6 C 2,283 55 43 0 0 NCEP 35 CV events ✓ ✓
Ridker et al., 2003 (44) 1992 10.1 C 14,719 54 0 0 0 Modified NCEP 24 CV events
CHD events
Rutter et al., 2004 (59) 1991 6.9 C 3,037 54 45 0 0 NCEP 24 CV events ✓
Sattar et al., 2003 (45) 1989 4.9 C 6,447 55 100 0 0 Modified NCEP 26 CHD events ✓ ✓
Schillaci, 2004 (60) 1988 4.1 M 1,742 50 55 0 6 Modified NCEP 34 CV events
CHD events
✓ ✓
Sprecher et al., 2000 (35) 1987 8.2 M 6,428 62 81 100 20 Other 12 Death ✓
Stern et al., 2004 (61) 1984 7–8 C 2,570 X X 0 X WHO
NCEP
X
36
CV events ✓
Tenkanen et al., 1994 (29) 1981 5.0 C 2,035 47 100 0 3 Other X CHD events ✓ ✓
Trevisan et al., 1998 (30) 1978 7.0 C 4,056 47 55 X Other 15 Death
CV death
CHD death
Wilson et al., 1999 (32) 1971 16.0 C 3,577 X 49 0 X Other 19 CHD death
CHD events
Data are for subjects included in analyses of incident cardiovascular disease (CVD) or death, and may differ from the characteristics of the total study populations. Definitions for metabolic syndrome, outcomes, and biases are in the Methods section.
C  community; CHD  coronary heart disease; CV  cardiovascular; DM  diabetes mellitus; M  medical; MS  metabolic syndrome; NA  not applicable; NCEP  National Cholesterol Education Program; WHO  World Health Association; X  unknown.
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January 30, 2007:403–14 Meta-Analysis of Metabolic Syndromessessed coronary heart disease events (which in some
tudies included coronary heart disease death), 10 studies
ssessed cardiovascular deaths, 7 studies assessed coronary
eart disease death, and 12 studies assessed all-cause death
Table 1, outcomes). The loss-events ratio ranged from 0%
o 990%, and in 23 studies it was less than 10% (Table 1,
ttrition bias). Age, gender, smoking, and prevalent cardio-
ascular disease were simultaneously controlled for, when
ecessary, in half of the studies (Table 1, selection bias). Not
hown in the table, detection bias was controlled for in all
tudies. Selection, detection, and attrition biases were con-
omitantly limited in 12 studies (29,34,39,43,45,46,48,53,
5,56,60,62).
eta-analyses. Separate meta-analyses for each outcome
cardiovascular events, coronary heart disease events, cardio-
ascular death, coronary heart disease death, and all-cause
eath) demonstrated that the magnitude of risk for the
ifferent outcomes assessed in the studies was similar (Fig.
). This supported our strategy for subsequent analyses to
ool the risk estimates for studies reporting different out-
omes based on the hierarchies described earlier. The overall
ooled RR for incident cardiovascular events and death for
eople with the MetSyn was 1.78 (95% confidence interval
CI] 1.58 to 2.00) (Fig. 4).
In the 7 studies that provided separate risk estimates for
oth genders, the risk of incident cardiovascular events and
eath was higher for women compared with men (RR 2.63
s. 1.98, p  0.09). Other within-study subgroups were not
nalyzed, because the studies only rarely reported risk
stimates for subgroups other than gender.
Significant heterogeneity existed between studies (I2 
2%), and we conducted the planned between-study sub-
roup analyses to investigate its sources. The RR of cardio-
ascular events and death was significantly different between
he WHO criteria, NCEP criteria, factor analysis, and other
riteria (2.06 vs. 1.67 vs. 2.68 vs. 1.35, p  0.005).
Figure 3 RR and 95% CI for Metabolic Syndrome and Incident
The diamonds represent the pooled relative risk (RR) and 95% confidence interval
each outcome. Some studies assessed more than 1 outcome. CHD  coronary heariability between studies that used “other” definitions
ere due to chance (I2  0%), as was nearly all of the
ariability between studies that used factor analysis (I2 
%); however, there were still large inconsistencies between
tudies using WHO and NCEP criteria (both I2 75%).
his heterogeneity was not explained by use of different
besity metrics (body mass index vs. waist circumference or
aist-to-hip ratio vs. either) (p  0.7).
We compared subgroups and studies that included only
iabetic patients with those that excluded diabetic patients
RR 1.51 vs. 1.69), those that included only coronary heart
isease patients to those that excluded coronary heart
isease patients (RR 2.68 vs. 1.94), and studies that in-
luded community subjects with those that included medical
atients (RR 1.69 vs. 1.70), but these comparisons did not
xplain the heterogeneity between studies (all p  0.10).
he background risk of the study populations (as deter-
ined by the event rate in the subjects without MetSyn) was
significant source of heterogeneity (p  0.047), and
etSyn posed a greater risk in populations with background
vent rates 10% compared with populations with back-
round event rates 10% (RR 1.96 vs. 1.43, p  0.04).
ttrition bias (p  0.02) but not selection bias (p  0.4)
ontributed to heterogeneity. Studies with high attrition
10% loss-events ratio) had a significantly higher risk of
ardiovascular events and death than those with low attri-
ion (RR 2.31 vs. 1.63, p  0.001).
Figure 5 shows the results of the meta-analysis of studies
hat simultaneously adjusted for MetSyn and its compo-
ents. The pooled results showed an increased risk of
ardiovascular disease or death in patients with MetSyn,
ven after controlling for its component risk factors (RR
.54, 95% CI 1.32 to 1.79). The results of the studies were
omogeneous (p  0.23); furthermore, the observed incon-
istency (I2  32%) suggested that most of the variability
etween these studies was due to chance.
ovascular Events and Death, by Specific Outcomes
r studies that assessed
sease; CV  cardiovascular.Cardi
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Meta-Analysis of Metabolic Syndrome January 30, 2007:403–14ensitivity analyses. We performed 3 sensitivity analyses
o test how robust the results of our meta-analysis were in
elation to its design and assumptions.
In the first, we included studies that had cohorts without
revalent cardiovascular disease and assessed incident coronary
eart disease events (Fig. 6). After removal of 2 outliers
29,44), the pooled RR was 1.49 (95% CI 1.37 to 1.61), and
here was no inconsistency (test of homogeneity p 0.8; I2
%). The first outlier (44) did not control for gender or
moking and had a very high loss-events ratio (161%), both of
hich introduce bias that could have increased its risk estimate.
he other outlier (29) was designed as a study of risk factor
lustering, rather than MetSyn per se, and thus the compo-
ents and their thresholds were dissimilar from the other
tudies (e.g., it did not incorporate any measure of obesity).
In the second sensitivity analysis, we included only the 12
Figure 4 RR and 95% CI for Metabolic Syndrome and Incident
Studies are listed in chronological order by year that their cohorts were created (e
able analyses of incident cardiovascular disease and death, and may differ from th
lines represent the 95% confidence interval (CI) for studies. The diamond representudies (listed earlier) that simultaneously limited selection, oetection, and attrition biases, since these are well recognized
nd important contributors to systematic error in observational
tudies. The results of this analysis were similar to those of the
verall analysis (RR 1.58, 95% CI 1.34 to 1.87), with similar
nconsistency across studies (I2  75%).
For the last sensitivity analysis, we re-analyzed the
riginal data after excluding 1 study (28), which itself was a
eta-analysis and potentially introduced error related to the
nreported but possible heterogeneity of its included co-
orts. Removing this study did not account for the under-
ying heterogeneity among studies (I2  81%) and did not
hange the general results (RR 1.83, 95% CI 1.62 to 2.07).
ublication bias. The funnel plot was asymmetric (Fig. 7,
lue), suggesting small-study bias (either the absence of or
nability to find studies with smaller or negative risk
stimates) or unexplained heterogeneity. The fail-safe n for
ovascular Events and Death
or the last study listed, which includes multiple cohorts). Results are for avail-
ults of the total study populations. Boxes represent the relative risk (RR), and
pooled RR, and its width represents its 95% CI.Cardi
xcept f
e res
ts theur pooled analysis is 3,846, which is reassuring since it is
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January 30, 2007:403–14 Meta-Analysis of Metabolic Syndromeery unlikely that there are over 100 unpublished or undis-
overed studies for every 1 study we found. The trim-and-
ll method imputed missing studies and recalculated our
ooled risk estimate (Fig. 7, red). The imputed RR was 1.68
95% CI 1.48 to 1.91), which is similar to our original risk
stimate, suggesting that the apparent publication bias in
his area is insufficient to affect our results or interpretations
n a meaningful way.
Figure 5 RR and 95% CI for Metabolic Syndrome and Incident
That Simultaneously Included Metabolic Syndrome an
All studies excluded people with prevalent cardiovascular disease, and 1 study (45
study) (62), body mass index (45), C-reactive protein (45), creatinine (60), left ven
relative risk (RR) for individual studies and are proportional to their weight in the a
resents the pooled RR, and its width represents its 95% CI. BP  hypertension or
ate included.
Figure 6 RR and 95% CI for Incident Coronary Heart Disease E
Results are for available analyses of incident coronary heart disease events, and
risk (RR) for individual studies and are proportional to their weight in the analysis,
pooled RR, and its width represents its 95% CI.iscussion
his study found that the current evidence, drawn from a
arge number of longitudinal studies that included 172,573
eople, indicates a significantly increased risk of cardiovas-
ular events and death in people with the MetSyn. The data
emonstrate that the cardiovascular risk conferred by the
etSyn was a third higher in women than it was in men.
ovascular Events and Death in Studies
e of its Components Into Multivariable Models
uded women. “Other” covariates included race (62), study site (in a multicenter
r hypertrophy (60), and cigarette smoking (45,60,62). The boxes represent the
, and the lines represent their 95% confidence intervals (CIs). The diamond rep-
ed systolic or diastolic blood pressure; Glu  fasting hyperglycemia; X  covari-
in Patients Without Prevalent Cardiovascular Disease
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Meta-Analysis of Metabolic Syndrome January 30, 2007:403–14he best evidence came from the studies in which people
ithout coronary heart disease were followed for incident
oronary heart disease events, which except for 2 outlying
tudies showed a slightly attenuated but similar and highly
omogeneous risk compared with the overall analysis. The
ost compelling evidence comes from our pooled analysis of
tudies that simultaneously adjusted in multivariable models
or both MetSyn and its components. The analysis of these
ethodologically rigorous and statistically homogeneous
tudies demonstrates that the MetSyn confers cardiovascu-
ar risk beyond that which is associated with its component
isk factors.
Our findings may shed light on important methodologic
ssues that created difficulty in making strong inferences
rom previous studies’ results. We found that many of these
ohort studies were methodologically limited by a high
egree of attrition bias. Subjects who were originally en-
olled but then were lost to follow-up can affect the risk
stimate, especially if the numbers lost are a large proportion
f (or in some of the studies we included, multiples of) the
umber of outcome events. We found that this attrition bias
as a significant source of variability in study results and
arkedly overestimated the cardiovascular risk associated
ith the MetSyn, while studies that limited this bias had a
ooled risk similar to that of the overall analysis.
The data reveal that definitions of MetSyn based on
actor analysis were far more predictive of cardiovascular
vents and death than were other definitions. Since factors
re created by integrating highly correlated risk factors in
he specific population being studied, this may be expected.
t should be recognized, however, that factors are statistical
Figure 7 Publication Bias and Its Potential Impact
The blue circles represent individual studies, the blue lines are the funnel plot, an
analysis. The red circles represent imputed studies, and the red lines represent t
meta-analysis, after adjusting for publication bias. Log (RR)  logarithm of the RRhenomena that cannot be applied readily to clinical prac- tice. Our findings show that the WHO-based criteria were
etter than NCEP-based criteria in predicting cardiovascu-
ar events and death, and that the substitution of body mass
ndex for waist circumference or waist-to-hip ratio in these
riteria did not appear to affect their robustness.
Limitations of our review include the inherent assump-
ions of meta-analysis. Since individual patient data were
navailable, we used aggregate data as reported in published
rticles (or as provided by their authors). This commonly
sed approach may not detect and cannot solve method-
logic problems affecting the primary studies. Also, our
nterpretations of between-study subgroup analyses may be
ess valid than within-study subgroup analyses, and there is
risk of type I error due to multiple testing in our analyses.
he strengths of our review include its exhaustive search
trategy, which likely captured most relevant studies. Also,
he success in procuring data from most study authors
vercame the lack of key data in published reports. The
rincipal strengths of our study are the fundamental
trengths of meta-analysis, which overcome selective and
otentially biased inclusion and weighing of articles’ results
hen interpreting the evidence, which can occur with
arrative reviews.
Our findings are applicable to clinical practice. Only few
f the studies in our analysis were published before devel-
pment of the 2003 NCEP guidelines designed to aid
linicians in recognizing and targeting MetSyn. Whether
he association between MetSyn and cardiovascular risk is
ufficient to support aggressive intervention for these pa-
ients was subject of debate, but the strength of the evidence
bout the association is now even clearer. Clinicians can use
blue diamond is the relative risk (RR) and 95% confidence interval for the meta-
usted funnel plot. The red diamond is the RR and 95% confidence interval for the
standard error.d the
he adj
; SE his evidence as motivation when counseling patients. Of
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January 30, 2007:403–14 Meta-Analysis of Metabolic Syndromeote, our analyses neither support nor refute the role of
nsulin resistance or any other mechanism as mediators of
he observed association between MetSyn and cardiovascu-
ar risk. Furthermore, our analyses do not yield therapeutic
nferences.
These studies were conducted in diverse populations,
ncluding many rural and urban regions of the U.S., Nor-
ay, Sweden, Finland, the Netherlands, Scotland, England,
pain, Italy, Poland, Turkey, and Japan. People in develop-
ng countries, where obesity and its comorbidities are
ecoming more prevalent, are underrepresented in the
urrent data. Only 1 original article included in our study
sed criteria apparently modified to account for different
thnic characteristics (58). The 2005 International Diabetes
ederation Consensus (63), which provides a “worldwide”
efinition of the MetSyn that applies different measures
f obesity for different ethnicities, should be incorporated
n future research. Also requiring further study are
hildren and young adults, in whom identification of
etSyn may have the greatest impact on public health if
t leads to successful interventions to prevent cardiovas-
ular disease.
Given the cumulative results of these studies, investiga-
ors should design and conduct large randomized trials of
ggressive dietary, lifestyle, and pharmacologic interventions
n people with MetSyn. Our findings suggest that in
ddition to targeting individual cardiovascular risk factors,
rimary prevention trials should study interventions that
ddress the MetSyn as 1 entity.
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